A Phase 3b, Multi-Center, Randomized-withdrawal, Placebo-Controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45-120mg/day, Split-dose) in Subjects with Chronic Kidney Disease Stage 4 due to Autosomal Dominant Polycystic Kidney Disease.